A European Conference Just Asked the Unglamorous Question: Who Actually Pays for Psychedelic Therapy?
Reporting from ICPR 2026 (the Interdisciplinary Conference on Psychedelic Research) in Haarlem, Netherlands, Lucid News' Floris Wolswijk — who also runs the analytics firm Blossom and spoke on a conference panel about whether European health systems can actually afford psychedelic treatment once it's approved — lays out the gap most US coverage skips: approval is not the same as access. Several European countries have research-grade or early-access frameworks for psychedelics already (our own legal status directory tracks Switzerland's and the Netherlands' specifically), but getting a drug approved doesn't automatically mean a national health system will pay for it, and Europe's fragmented, country-by-country reimbursement systems make that a much harder problem than it is in a single-payer-adjacent US private insurance model.
It's a useful corrective to the US-centric framing most psychedelic coverage defaults to — the next real bottleneck in Europe isn't regulatory, it's financial, and nobody's solved it yet.